Phospho-Histone H1 (Thr17) Antibody

What is Histone H1 phosphorylation at Thr17 and its biological significance?

Histone H1 phosphorylation at threonine 17 (Thr17) is a post-translational modification that plays crucial roles in chromatin structure regulation and gene expression. Histone H1 functions as a linker histone that interacts with DNA between nucleosomes, contributing to the compaction of chromatin into higher-order structures . The phosphorylation at Thr17 specifically alters the binding properties of H1 to linker DNA, affecting chromatin accessibility and subsequently influencing transcriptional regulation .

This modification is particularly important because it acts as a regulator of individual gene transcription through its effects on chromatin remodeling, nucleosome spacing, and even DNA methylation processes . The phosphorylation status of H1 at Thr17 changes dynamically during cellular processes such as the cell cycle, DNA damage response, and differentiation, making it an important marker for studying these fundamental biological processes.

How do I distinguish between different Histone H1 variants in my phosphorylation studies?

When designing experiments to study specific H1 variants, consider the following methodological approach:

• Antibody selection: Choose antibodies with validated specificity for particular H1 variants. For example, antibodies specific to phosphorylated H1.3 (T17) or H1.4 (T17) are available . Some antibodies may detect multiple variants, such as those that recognize both H1.3 and H1.4 phosphorylated at T17 .

• Validation techniques:

  • Western blotting with purified H1 variant proteins as controls

  • Using cell lines with knockout or knockdown of specific H1 variants

  • Peptide competition assays with synthetic phosphopeptides corresponding to each variant

• Sequence comparison: Be aware of the sequence similarity around the Thr17 phosphorylation site across different H1 variants. H1.3 (HIST1H1D) and H1.4 (HIST1H1E) share high sequence homology in this region, making specific detection challenging .

For absolute specificity, consider using recombinant protein expression systems or genetically modified cell lines expressing tagged versions of individual H1 variants.

What are the validated applications for Phospho-Histone H1 (Thr17) antibodies in research?

Phospho-Histone H1 (Thr17) antibodies have been validated for multiple research applications, each with specific optimized protocols:

• Western Blotting (WB): Successfully used to detect endogenous levels of Histone H1 protein when phosphorylated at T17 . Dilution ranges from 1:300-1:5000 are typically recommended , with validation demonstrated in cell lines such as SKOV3 .

• Immunohistochemistry (IHC): Both paraffin-embedded (IHC-P) and general IHC applications have been validated . For IHC-P, optimal dilutions range from 1:200-1:400 .

• Immunofluorescence/Immunocytochemistry (IF/ICC): Useful for subcellular localization studies of phosphorylated H1, with recommended dilutions of 1:50-1:200 .

• ELISA: Both conventional ELISA and specialized cell-based ELISA formats are applicable . The cell-based ELISA approach is particularly valuable for high-throughput screening of compounds that affect H1 phosphorylation status .

Each application requires specific sample preparation techniques. For instance, nuclear extraction protocols must preserve phosphorylation status, typically requiring phosphatase inhibitors during sample preparation.

How can I optimize Western blotting protocols specifically for Phospho-Histone H1 (Thr17) detection?

For optimal detection of Phospho-Histone H1 (Thr17) by Western blotting, follow these specialized methodological guidelines:

• Sample preparation:

  • Extract histones using acid extraction (0.2N HCl or 0.4N H2SO4) to efficiently isolate and concentrate histone proteins

  • Include phosphatase inhibitors (10mM NaF, 1mM Na3VO4, 10mM β-glycerophosphate) in all buffers

  • Maintain samples at 4°C throughout processing to preserve phosphorylation

• Gel electrophoresis and transfer:

  • Use 15% SDS-PAGE gels for optimal resolution of the ~21-23 kDa histone H1 proteins

  • Consider using Phos-tag™ gels for enhanced separation of phosphorylated species

  • Transfer to PVDF membrane (rather than nitrocellulose) at lower voltage (30V) overnight at 4°C

• Antibody incubation:

  • Block membranes with 5% BSA (not milk) in TBST to prevent phosphatase activity

  • Dilute primary antibody at 1:1000 in 5% BSA/TBST and incubate overnight at 4°C

  • Use HRP-conjugated anti-rabbit IgG secondary antibody at 1:5000 dilution

• Controls and validation:

  • Include a total Histone H1 antibody on a parallel blot for normalization

  • Consider lambda phosphatase treatment of a duplicate sample as a negative control

  • The SKOV3 cell line has been validated as a positive control for Phospho-Histone H1 (Thr17)

Following this optimized protocol can enhance signal specificity and reduce background when detecting Phospho-Histone H1 (Thr17).

How specific are commercially available Phospho-Histone H1 (Thr17) antibodies?

The specificity of Phospho-Histone H1 (Thr17) antibodies varies considerably depending on the immunogen design and production method. Based on available data:

• Phospho-specific recognition: High-quality antibodies can specifically detect Histone H1 only when phosphorylated at T17, distinguishing it from unphosphorylated forms . For example, the rabbit polyclonal antibody described in source "detects endogenous levels of Histone H1 protein only when phosphorylated at T17."

• Histone variant specificity:

  • Some antibodies are designed to recognize specific H1 variants such as H1.4 (HIST1H1E)

  • Others may detect multiple variants, like the monoclonal antibody that recognizes both H1.3 (T17) and H1.4 (T17)

  • The specificity is determined by the immunogen used; for example, antibodies raised against "synthesized peptide derived from human Histone H1 around the phosphorylation site of T17" or "synthetic phospho-peptide around Thr17 of human H1.4"

• Species cross-reactivity: Most characterized antibodies demonstrate reactivity across multiple species:

  • Human, Mouse, and Monkey

  • Human and Mouse

  • Human, Mouse, and Rat

To confirm antibody specificity for your particular application, validation experiments should include:

• Peptide competition assays with phosphorylated and non-phosphorylated peptides

• Testing in cell lines treated with kinase inhibitors that prevent H1 phosphorylation

• Comparison of reactivity in wild-type versus phospho-site mutant (T17A) constructs

What are effective controls to validate Phospho-Histone H1 (Thr17) antibody specificity in experimental designs?

Implementing rigorous controls is essential for validating antibody specificity when working with Phospho-Histone H1 (Thr17) antibodies:

• Positive controls:

  • Cell lines with known high levels of Histone H1 T17 phosphorylation (e.g., SKOV3 cells have been validated for this purpose)

  • Cells treated with agents that enhance H1 phosphorylation (e.g., okadaic acid, calyculin A)

  • Recombinant phosphorylated H1 protein or synthetic phosphopeptides corresponding to the T17 region

• Negative controls:

  • Lambda phosphatase treatment of samples to remove phosphorylation

  • Cells treated with CDK inhibitors (as CDKs are primary kinases for H1 phosphorylation)

  • Competition with excess phospho-peptide to block specific antibody binding

  • Genetic models: Cells expressing T17A mutant H1 that cannot be phosphorylated

• Parallel detection strategies:

  • Dual labeling with antibodies against total H1 and phospho-H1 (T17)

  • Use of two different phospho-specific antibodies (monoclonal and polyclonal) targeting the same site

  • Correlation with mass spectrometry data to confirm phosphorylation status

• Experimental validation approach:

  • Western blotting: Should show a single band at the expected molecular weight (~21-23 kDa) that disappears upon phosphatase treatment

  • Immunofluorescence: Nuclear staining pattern that changes with cell cycle phases

  • Signal modulation: Phosphorylation signal should increase/decrease in response to appropriate stimuli

How can Phospho-Histone H1 (Thr17) antibodies be utilized in cell cycle and chromatin dynamics research?

Phospho-Histone H1 (Thr17) antibodies serve as powerful tools for investigating cell cycle regulation and chromatin structural changes:

• Cell cycle phase-specific analysis:

  • Histone H1 phosphorylation increases during S phase and peaks in mitosis

  • Using Phospho-Histone H1 (Thr17) antibodies in immunofluorescence allows visualization of this dynamic process

  • Combine with flow cytometry for quantitative assessment of H1 phosphorylation levels across cell cycle phases

  • Protocols can integrate EdU/BrdU labeling with Phospho-Histone H1 (Thr17) staining to correlate with DNA replication

• Chromatin compaction studies:

  • Since H1 functions in the condensation of nucleosome chains into higher-order structures , Phospho-Histone H1 (Thr17) antibodies can track how phosphorylation affects this process

  • Combine with super-resolution microscopy to visualize chromatin structural changes

  • Chromatin immunoprecipitation (ChIP) using Phospho-Histone H1 (Thr17) antibodies can map genomic regions where this modification occurs

• Gene regulation mechanisms:

  • H1 acts as "a regulator of individual gene transcription through chromatin remodeling, nucleosome spacing and DNA methylation"

  • Use colorimetric cell-based ELISA kits to screen for "effects that various treatments, inhibitors (ie. siRNA or chemicals), or activators have on Histone H1 (Phospho-Thr17)"

  • Implement ChIP-seq with Phospho-Histone H1 (Thr17) antibodies to correlate this modification with transcriptional activity

• Signaling pathway analysis:

  • Study kinase pathways that regulate H1 phosphorylation using Phospho-Histone H1 (Thr17) antibodies as readouts

  • Experimental design can include kinase inhibitors followed by quantitative immunoblotting or ELISA to measure Thr17 phosphorylation levels

These advanced applications enable researchers to connect molecular-level histone modifications to broader cellular processes such as proliferation, differentiation, and genome stability.

What are the methodological approaches for studying Histone H1 (Thr17) phosphorylation in different cellular contexts?

Investigating Histone H1 (Thr17) phosphorylation across various cellular contexts requires tailored methodological approaches:

• Cancer research applications:

  • Compare Phospho-Histone H1 (Thr17) levels between normal and cancer cells using immunoblotting

  • SKOV3 ovarian cancer cells have been validated for Phospho-Histone H1 (Thr17) detection

  • Use cell-based ELISA kits to screen cancer cell lines for altered H1 phosphorylation patterns

  • Develop tissue microarrays with IHC staining to correlate Phospho-Histone H1 (Thr17) with clinicopathological features

• DNA damage response studies:

  • Track temporal changes in H1 phosphorylation following genotoxic stress

  • Experimental design: Treat cells with DNA-damaging agents, harvest at time intervals, perform western blotting with Phospho-Histone H1 (Thr17) antibodies

  • Combine with γH2AX staining to correlate H1 phosphorylation with DNA damage foci

• Developmental biology applications:

  • H1 variants like H1.4 have tissue-specific expression patterns

  • Immunohistochemistry protocols using Phospho-Histone H1 (Thr17) antibodies can be optimized for various tissue types

  • For embryonic studies, implement whole-mount immunofluorescence with confocal microscopy

• Quantitative analysis approaches:

  • Cell-based ELISA kits provide a "convenient, lysate-free, high throughput and sensitive assay" for measuring "relative amounts of Histone H1 (Phospho-Thr17) in cultured cells"

  • Assay range accommodates >5000 cells/well

  • For single-cell resolution, combine immunofluorescence with automated image analysis

  • For population-level studies, use flow cytometry with Phospho-Histone H1 (Thr17) antibodies

• Species-specific considerations:

  • Most antibodies demonstrate cross-reactivity among Human, Mouse, and/or Rat samples

  • Optimize antibody concentrations when switching between species (typical dilutions range from 1:50-1:5000 depending on application)

Each methodological approach should incorporate appropriate controls and validation steps to ensure reliable detection of Phospho-Histone H1 (Thr17) in the specific cellular context being studied.

What are common challenges in detecting Phospho-Histone H1 (Thr17) and how can they be overcome?

Researchers frequently encounter several technical challenges when working with Phospho-Histone H1 (Thr17) antibodies. Here are methodological solutions to address these issues:

• Loss of phosphorylation during sample preparation:

  • Problem: Endogenous phosphatases can rapidly dephosphorylate histones during extraction

  • Solution: Add phosphatase inhibitor cocktails (including 10mM NaF, 1mM Na3VO4, 10mM β-glycerophosphate) to all buffers

  • Maintain samples at 4°C throughout processing

  • Consider trichloroacetic acid (TCA) precipitation to rapidly denature phosphatases

• Cross-reactivity with other phosphorylated histones:

  • Problem: Some antibodies may detect multiple phosphorylated histone variants

  • Solution: Use antibodies with validated specificity for Histone H1 phosphorylated at T17

  • Perform peptide competition assays with phosphorylated and non-phosphorylated peptides

  • Include proper controls such as lambda phosphatase treatment

• High background in immunostaining:

  • Problem: Non-specific binding causing high background

  • Solution: Optimize blocking conditions (5% BSA is often more effective than milk for phospho-antibodies)

  • Increase washing steps and duration

  • For ICC/IF applications, dilute antibodies in the range of 1:50-1:200

• Inconsistent results between experiments:

  • Problem: Variability in phosphorylation levels due to cell cycle differences

  • Solution: Synchronize cells when possible

  • Perform time-course experiments

  • Use cell-based ELISA kits which can "monitor Histone H1 (Phospho-Thr17) protein expression profile in cells" with high reproducibility

• Low signal in Western blotting:

  • Problem: Insufficient concentration of the phosphorylated form

  • Solution: Enrich for histones using acid extraction methods

  • Consider using signal enhancement systems

  • Optimize antibody concentration (1:300-5000 range for WB applications)

  • Use PVDF membranes instead of nitrocellulose for better protein retention

These troubleshooting approaches will help ensure more reliable and reproducible results when detecting Phospho-Histone H1 (Thr17) in various experimental settings.

How do I optimize immunofluorescence protocols for detecting nuclear Phospho-Histone H1 (Thr17)?

Optimizing immunofluorescence (IF) protocols for nuclear Phospho-Histone H1 (Thr17) detection requires specialized techniques to preserve phosphorylation status while ensuring nuclear accessibility:

• Cell fixation and permeabilization:

  • Preferred fixation: 4% paraformaldehyde for 10-15 minutes at room temperature

  • Avoid methanol fixation which can reduce phospho-epitope detection

  • Permeabilization options:

    • 0.1-0.2% Triton X-100 for 5-10 minutes (standard)

    • 0.5% Saponin (gentler alternative that better preserves nuclear structure)

    • Pre-extraction with 0.1% Triton X-100 in CSK buffer before fixation can enhance signal-to-noise ratio

• Antibody incubation optimization:

  • Dilution range: 1:50-1:200 for most Phospho-Histone H1 (Thr17) antibodies in IF applications

  • Extended incubation: Overnight at 4°C typically yields better results than shorter incubations

  • Diluent composition: PBS with 3% BSA and 0.1% Triton X-100 supplemented with phosphatase inhibitors

• Signal enhancement strategies:

  • Tyramide signal amplification for weak signals

  • Use of high-sensitivity detection systems (e.g., Alexa Fluor 488 or 594 secondaries)

  • Counterstaining nuclei with DAPI helps confirm nuclear localization

  • Z-stack imaging with deconvolution for improved spatial resolution

• Controls and validation:

  • Include cells treated with phosphatase to confirm specificity

  • Perform dual staining with total Histone H1 antibodies to normalize signal

  • Compare mitotic versus interphase cells (mitotic cells should show higher phosphorylation)

  • Peptide competition controls to verify signal specificity

• Imaging considerations:

  • Confocal microscopy recommended for precise nuclear localization

  • Consistent exposure settings between samples for quantitative comparisons

  • Avoid photobleaching of phospho-epitopes by minimizing exposure to excitation light

• Quantification approach:

  • Measure nuclear fluorescence intensity using image analysis software

  • Calculate nucleus-to-cytoplasm ratio to control for background

  • For heterogeneous populations, consider single-cell analysis approaches

Following these optimization steps will result in more reliable and reproducible immunofluorescence detection of Phospho-Histone H1 (Thr17) in nuclear contexts.